Primary Record
Dolutegravir
Note: Only for scientific research or as raw materials for production.
- In stock
- 3,502 g
- Purity
- 98.1 %
- CAS
- 1051375-16-6
Compound Identifiers & Properties
- CAS
- 1051375-16-6
- PubChem CID
- 54726191
- SMILES
- C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
- Canonical SMILES
- C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
Names & Synonyms
- Dolutegravir
- Tivicay
- 1051375-16-6
- GSK1349572
- dolutegravirum
- Cabotegravir
- Soltegravir
- Dolutegravir?
- Dolutegravir DTG
- S/GSK1349572
- Dolutegravir (GSK1349572)
- Dolutegravir [USAN]
- Tivicay (TN)
- GSK 1349572
- GSK-1349572
- Dolutegravir (USAN)
- Dolutegravir free acid
- DKO1W9H7M1
- 3s3m
- 3s3n
- 3s3o
- Dolutegravir (Standard)
- Dolutegravir [USAN:INN]
- RefChem:56964
- UNII-DKO1W9H7M1
- DOLUTEGRAVIR [MI]
- DOLUTEGRAVIR SODIUM
- DOLUTEGRAVIR [INN]
- cc-13
- CHEBI:76010
- D00YZD
- D0W0TW
- DOLUTEGRAVIR [VANDF]
- Dolutegravir Sodium ( API)
- S-349572
- SCHEMBL82071
- HSDB 8152
- MLS006011137
- DOLUTEGRAVIR [WHO-DD]
- C20H19F2N3O5
- DTXSID90909356
- MFCD20488027
- GTPL7365
- orb1300988
- QCR-34
- CHEMBL1229211
- SCHEMBL15397915
- SCHEMBL29357473
- GSK1349572A
- J05AX12
- RHWKPHLQXYSBKR-BMIGLBTASA-N
- S-GSK1349572
- DTXCID701338419
- GLXC-90267
- AOB87150
- EX-A1695
- 1051375-16-6 (free)
- ABP000915
- BDBM50062551
- EBC-27030
- HY-13238R
- s2667
- ZINC58581064
- AKOS025396657
- S/GSK-1349572
- ACN-041355
- BCP9000620
- C20-H19-F2-N3-O5
- CCG-268876
- CS-0454
- DB08930
- FD43372
- RL00238
- (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide
- Dolutegravir (0.1 mg/mL in Methanol)
- NCGC00346629-01
- NCGC00346629-02
- NCGC00346629-06
- NCGC00346629-11
- AC-28371
- AS-75277
- BC638753
- HY-13238
- SC-85939
- SMR004702915
- (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- AB0033823
- A4074
- NS00099377
- X7595
- J3.008.741K
- S/GSK1349572,GSK1349572
- D10066
- Q-4931
- EN300-7409916
- A854801
- F799806
- Q937224
- (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide
- (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
- Z2235801952
- 1062161-90-3, WYE687, WYE 687
- B0084-438457
- 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-
- DTG
- (14C)-(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-(1,3)oxazino(3,2-a)pyrido(1,2-d)pyrazine-9-carboxamide
- (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0(3),?]tetradeca-10,13-diene-13-carboxamide
- (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0,3,8]tetradeca-10,13-diene-13-carboxamide
- (4R,12.ALPHA.S)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12.ALPHA.-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-.BETA.)(1,3)OXAZINE-9-CARBOXAMIDE
- (4R,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide
- (4R,12aS)-N-((2,4-difluorophenyl)methyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido(5,6)pyrazino(2,6-b)(1,3)oxazine-9-carboxamide
- (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-a]pyrido[1,2-d]pyrazine-9-carboxamide
- (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide
- (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1,2:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[[?]:[?]]pyrazino[[?]][1,3]oxazine-9-carboxamide
- (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide
- (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- (4R,9aS)-5-Hydroxy-3,4,9,9a-tetrahydro-7-[(2,4-difluorobenzyl)carbamoyl]-4-methyl-2H-1-oxa-4a,8a-diazaanthracene-6,10-dione
- (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid-2,4 difluorobenzylamide
- (4R,9aS)-N-(2,4-Difluorobenzyl)-5-hydroxy-3,4,6,9,9a,10-hexahydro-4-methyl-6,10-dioxo-2H-1-oxa-4a,8a-diazaanthracene-7-carboxamide
- (4R,9aS)-N-(2,4-Difluorobenzyl)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diazaanthracene-7-carboxamide
- 1051375-19-9
- 1172581-47-3
- 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)
- 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir; GSK 1349572; S@fs:GSK1349572; Soltegravir; Tivicay; GSK 1349572B
- 900515-16-4
- DLU
- Dolutegravi;GSK1349572;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;S/GSK1349572(GSK1349572);Dolutegravir;GSK1349572(dolutegravir);S/GSK1349572